Nachrichten zur Pfizer Aktie

Dow edges higher but Pfizer drops on obesity pill setback

9:40am: Markets mixed ahead of ISM, Powell US stocks opened mixed as investors looked ahead to ISM manufacturing data and…

: Pfizer’s stock falls 4% after saying it will not move to Phase 3 trial of weight-loss drug as twice-daily formation

Pfizer Inc.’s stock PFE fell 4% premarket Friday, after the company said it’s not planning to push ahead to a…

Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects

Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug,…

Pfizer Stocks Post-Covid Hangover Gets Worse

Pfizer was a darling stock during the pandemic thanks to its life-saving Covid-19 vaccine. But the companys shares have been…

Texas AG Sues Pfizer Over Covid Vaccine Effectiveness

Attorney General Ken Paxton alleges Pfizer also attempted to silence critics of its vaccine.…

Pfizer is sued by Texas over COVID-19 vaccine claims By Reuters

Pfizer is sued by Texas over COVID-19 vaccine claims…

Subdermal Contraceptive Implants Market revenue to reach USD 3 Billion by 2036, says Research Nester

Major subdermal contraceptive implants market players include Merck & Co., Inc., Shanghai Dahua Pharmaceutical Co., Ltd, Bayer AG, Wyeth Pharmaceuticals,…

[Latest] Global Organ Transplantation Market Size/Share Worth USD 21.5 Billion by 2032 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Pancreatic Cancer Market revenue to reach USD 36 Billion by 2036, says Research Nester

Key pancreatic cancer market players include Amgen Inc., Novartis AG, Pfizer Inc., Aduro Biotech Inc., Clovis Oncology Inc., NewLink Genetics…

Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

Eight Beaten-Down Stocks Including Pfizer and Hasbro That Look Like Bargains

…

Pfizer Inc. (PFE) 6th Annual Evercore ISI HealthCONx Conference (Transcript)

…

4 Large Drug Stocks to Watch as IBD Market Gains Traction

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players…

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®)…

Global Cold Pain Therapy Market Size Worth USD 2.92 Billion by 2032 | CAGR of 5.2%

The Global Cold Pain Therapy Market Size was valued at USD 1.76 Billion in 2022 and the Worldwide Cold Pain…

Global Printing Ink Market Size Worth USD 35.93 Billion by 2032 | CAGR of 6.7%

The Global Cold Pain Therapy Market Size was valued at USD 1.76 Billion in 2022 and the Worldwide Cold Pain…

How To Earn $500 A Month From Pfizer Stock

…

Mastercard, Pfizer Among 18 Companies To Announce Dividend Increases In December

…

dpa-AFX: JPMorgan belässt Pfizer auf Neutral - Ziel 34 Dollar

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Pfizer-Aktie mit Blick auf die Kursschwäche in diesem Jahr auf "Neutral"…

JPMorgan belässt Pfizer auf Neutral - Ziel 34 Dollar

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Pfizer-Aktie mit Blick auf die Kursschwäche in diesem Jahr auf…

Rising Global Prevalence of Skin Diseases Drives the Antipruritics Market, Future Market Insights Predicts Expansion at a 4.2% CAGR through 2034

The growing geriatric population, rising burden of skin diseases, and rising R&D on novel biopharmaceuticals. AbbVie Inc., Allergan, Merck &…

Pfizer: Abwärtspotenzial nach Ausverkauf ziemlich begrenzt - Aktienanalyse

New York (www.aktiencheck.de) - Pfizer-Aktienanalyse von J.P. Morgan Securities: Die Analysten von J.P. Morgan Securities bewerten die Aktie von Pfizer Inc.…

Synthetic Hormones Market Analysis Report 2023-2033, Featuring Profiles of Eli Lilly, Pfizer, Ferring, Merck, Novo Nordisk, Bayer, Novartis and More

Dublin, Nov. 27, 2023 (GLOBE NEWSWIRE) -- The "Global Synthetic Hormones Market: Focus on Product Type, Application, Route…

Global Glaucoma Treatment Market Size To Grow USD 10.5 Billion by 2032 | CAGR of 5.0%

The Global Glaucoma Treatment Market Size was valued at USD 6.4 Billion in 2022 and the Worldwide Glaucoma Treatment Market…

[Latest] Global Acne Treatment Market Size/Share Worth USD 18.77 Billion by 2032 at a 6.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

Pfizers stock price is at a three-year low. Is it time to buy?

This heavily sold-off pharma stock is a bargain, so is it time to buy?…

Europäisches Patentamt erklärt Moderna-Patent für nichtig

Frankfurt (Reuters) - Das Europäische Patentamt hat im Patentstreit zwischen den beiden Corona-Impfstoffherstellern BioNTech und Moderna ein mRNA-Patent des US-Biotechkonzerns…

Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips

…

Impfstoffentwickler: EU-Patentamt hat Moderna-Patent für nichtig erklärt

Ende August hatte die US-Biotech-Firma Moderna das Mainzer Unternehmen Biontech und dessen US-Partner Pfizer verklagt. Das Urteil fiel nun zugunsten…

Texas AG sues Pfizer over quality-control lapses in kids ADHD drug By Reuters

Texas AG sues Pfizer over quality-control lapses in kids ADHD drug…

Texas AG sues Pfizer for alleged Medicaid fraud over ADHD meds

…

Pfizer Is Working on Oral Alternative to Ozempic

Pfizer CEO Albert Bourla says the drug maker is hoping to develop an oral anti-obesity drug that can rival Ozempic.…

Basilea Pharmaceutica AG: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese Region aus

Allschwil, 20. November 2023 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,…

GNW-Adhoc: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese Region aus

^Allschwil, 20. November 2023 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,…

GNW-Adhoc: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr fü...

^Allschwil, 20. November 2023Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutischesUnternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zuhelfen,…

GlobeNewswire: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese Region aus

Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese…

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

Allschwil, Switzerland, November 20, 2023…

Pfizer Stock: Cheap But Will Remain Cheap, For Now

…

Why the Cheapest Stock in the S&P 500 Is No Bargain

Viatris is the old generic drug company Mylan, acquired by Pfizer and merged with its Upjohn division. The stock has…

AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell? @themotleyfool #stocks $ABBV $PFE

Both companies share prices have slipped recently.…

AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?

Both companies share prices have slipped recently.…

Pfizers (PFE) New Products May Drive Long-Term Sales Growth

Though Pfizers (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is…

Eli Lillys Olumiant and Pfizers Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain

Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market…

dpa-AFX ProFeed